Literature DB >> 30444507

Synthesis of chiral chromanols via a RuPHOX-Ru catalyzed asymmetric hydrogenation of chromones.

Yujie Ma1, Jing Li1, Jianxun Ye1, Delong Liu1, Wanbin Zhang2.   

Abstract

Chiral chromanols and their derivatives have been synthesized via a RuPHOX-Ru catalyzed asymmetric hydrogenation of chromones in high yields, >20 : 1 drs and with up to 99.9% ee. Control experiments show that the reaction undergoes two sequential asymmetric hydrogenation steps of the C[double bond, length as m-dash]C and C[double bond, length as m-dash]O double bonds. The reaction could be performed on a gram-scale with a relatively low catalyst loading (up to 1000 S/C), and the resulting products can be transformed to several biologically active compounds.

Entities:  

Year:  2018        PMID: 30444507     DOI: 10.1039/c8cc07787h

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  4 in total

1.  Further Developments and Applications of Oxazoline-Containing Ligands in Asymmetric Catalysis.

Authors:  Robert Connon; Brendan Roche; Balaji V Rokade; Patrick J Guiry
Journal:  Chem Rev       Date:  2021-05-21       Impact factor: 60.622

2.  Effects of a forming process on the properties and structure of RANEY®-Ni catalysts for the hydrogenation of 1,4-butenediol.

Authors:  Xianlong Gao; Wenlong Mo; Fengyun Ma; Tsubaki Noritatsu; Hongli Wu; Xing Fan
Journal:  RSC Adv       Date:  2020-02-05       Impact factor: 4.036

3.  Ir/f-Ampha complex catalyzed asymmetric sequential hydrogenation of enones: a general access to chiral alcohols with two contiguous chiral centers.

Authors:  Wendian Li; Tilong Yang; Nan Song; Ruihao Li; Jiao Long; Lin He; Xumu Zhang; Hui Lv
Journal:  Chem Sci       Date:  2022-01-18       Impact factor: 9.825

4.  Stereoselective Iridium-N,P-Catalyzed Double Hydrogenation of Conjugated Enones to Saturated Alcohols.

Authors:  Bram B C Peters; Jia Zheng; Suppachai Krajangsri; Pher G Andersson
Journal:  J Am Chem Soc       Date:  2022-05-05       Impact factor: 16.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.